Phase 2 Type 1 Diabetes Trial, Recruiting NCT03970720 Sponsor: Simon Fisher Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Phase 2 Type 1 Diabetes Trial, Recruiting

NCT03970720
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Type 1 Diabetes.
  • People who have had diabetes for more than 5 years.
  • People whose average blood sugar level (measured by a blood test called HbA1c) is 9% or below.
  • People who are able to understand and agree to the study rules by signing a consent form.

Who may not be able to join:

  • People with a history of heart attack, irregular heartbeat, heart failure, or reduced blood flow to the heart.
  • People with a history of stroke or brain disease.
  • People who have had blockages in their urinary tract or difficulty passing urine.
  • People with serious liver disease.
  • People with low levels of red blood cells (anaemia), specifically a haemoglobin level below 11 g/dL.
  • Women who are pregnant, breastfeeding, or unable to use effective contraception during the study.
  • People with uncontrolled mania or a current major depressive disorder.
  • People who have previously had an allergic reaction or bad side effects from heparin (a blood-thinning medication).
  • People who cannot safely take a medication called metoclopramide — this includes those with a known allergy to it, a blockage in the digestive tract, uncontrolled high blood pressure, a tumour called pheochromocytoma, seizure disorders, Parkinson's disease, use of certain psychiatric medications within the past 6 months, use of benzodiazepine medications within the past month, use of certain antidepressants (MAOIs) or opioid pain medications within the past 14 days, active alcohol or drug misuse, or use of other sedating medications (confirm with trial site).
  • People who have taken part in another study looking at low blood sugar awareness or related conditions in the past 30 days.
  • People who are currently using an unblinded real-time continuous glucose monitor (a device that shows live blood sugar readings).
  • People who regularly need to take paracetamol (acetaminophen).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Simon Fisher, MD, PhD, University of Kentucky

Phone: 859-562-0473

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Simon Fisher
Registry
ClinicalTrials.gov
Start date
28 May 2019
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Blood Glucagon; Change in Blood Epinephrine; Change in Blood Norepinephrine; Change in Blood Cortisol; Change in Blood Pancreatic Polypeptide; Change in Hypoglycemia Symptom Recognition

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov